Answer
All combined hormonal contraceptives increase clot risk compared with non-use. The product information reports that this patch may have up to twice the VTE risk of combined contraceptives containing levonorgestrel, so individual risk factors must be assessed.
Sources for this answer
- EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch — Current selected SmPCemc · Summary of Product Characteristics
- UK Government